Vitamin K for prevention and treatment of skin rash secondary to anti-EGFR therapy
View Patent ↗The invention provides methods and compositions for treating and preventing a skin rash secondary to anti-epidermal growth factor receptor (EGFR) therapy, where the method comprises applying a vitamin K analog or a phosphatase inhibitor to the skin.
1. A method for treating a skin rash secondary to an anti-epidermal growth factor receptor (EGFR) therapy in a subject receiving said therapy, the method comprising applying vitamin K3 to the skin in an amount effective to treat the skin rash.
2. The method of claim 1 , wherein the anti-EGFR therapy is treatment with an anti-EGFR antibody.
3. The method of claim 2 , wherein the anti-EGFR antibody is cetuximab.
4. The method of claim 1 , wherein the anti-EGFR therapy is treatment with an EGFR tyrosine kinase inhibitor.
5. The method of claim 4 , wherein the EGFR tyrosine kinase inhibitor is gefitinib or erlotinib.
6. The method of claim 1 , wherein the vitamin K3 activates EGFR.
7. The method of claim 1 , wherein the vitamin K3 is formulated in a pharmaceutical formulation suitable for topical administration.
8. The method of claim 1 , wherein the vitamin K3 is applied to the face.
9. The method of claim 1 , wherein the vitamin K3 is applied to the trunk.
10. The method of claim 1 , comprising exposing skin cells to 0.01 mM vitamin K3.
11. The method of claim 1 , comprising exposing skin cells to 15 mM vitamin K3.
12. The method of claim 1 , comprising exposing skin cells to 30 mM vitamin K3.
13. The method of claim 1 , comprising exposing skin cells to 100 mM vitamin K3.
14. The method of claim 1 , comprising applying the vitamin K3 twice daily.
15. The method of claim 1 , comprising applying vitamin K3 daily.
16. The method of claim 1 , comprising applying the vitamin K3 every other day.